RARE

Ultragenyx Pharm

• TipRanks·1d ago

  Ultragenyx, Baylor Reach Settlement on DOJOLVI Patents

• Benzinga·1d ago

  Ultragenyx Settles DOJOLVI Patent Litigation With Navinta, Allowing Generic Entry Starting January 1, 2033; Or July 2033 With Pediatric Exclusivity; Similar Patent Litigation Against Other DOJOLVI Abbreviated New Drug Application Filers Related To DOJOLVI Remains Pending

• Simply Wall St·2d ago

  Is Ultragenyx Pharmaceutical (RARE) Below Fair Value Following Its $203 Million Voucher Sale?

• NASDAQ·3d ago

  FDA Drug Approvals In September 2026

• Simply Wall St·4d ago

  Voucher Sales Might Change The Case For Investing In Ultragenyx Stock (RARE)

• Dow Jones·4d ago

  Ultragenyx Pharma Price Target Announced at $16.00/Share by UBS

• Dow Jones·4d ago

  Ultragenyx Pharma Initiated at Neutral by UBS

• Benzinga·4d ago

  UBS Initiates Coverage On Ultragenyx Pharmaceutical with Neutral Rating, Announces Price Target of $16

• TipRanks·5d ago

  Ultragenyx Pharmaceutical (RARE) Receives a New Rating from a Top Analyst

• TipRanks·5d ago

  Ultragenyx initiated with a Neutral at UBS

• Seeking Alpha·5d ago

  FDA unveils rare disease initiative to enhance therapy development

• TipRanks·6d ago

  Ultragenyx: Non-Dilutive Capital and Clinical Catalysts Underscore Buy Rating and Unchanged $25 Price Target

• Dow Jones·6d ago

  Ultragenyx Pharmaceutical to Sell Priority Review Voucher for $203M

• Seeking Alpha·6d ago

  Ultragenyx to sell Fayuvi FDA priority review voucher for $203M

• NASDAQ·6d ago

  Ultragenyx To Sell Rare Pediatric Disease Priority Review Voucher For $203 Mln